CareDx Beats Q1 Estimates and Raises Full-Year Guidance, But Stock Slips
CareDx Inc (NASDAQ:CDNA) reported a blowout first quarter for 2026, smashing analyst expectations on both the top and bottom lines. The precision medicine company posted revenue of $117.7 million and non-GAAP earnings per share (EPS) of $0.34, significantly outpacing the consensus estimates of $106.1 million and $0.14 per share, respectively.
Despite the strong headline numbers, the stock saw a slight pullback in after-hours trading, declining by about 1.9% at the time of writing. This suggests that while the results were strong, some of the good news may have already been priced into the stock following a robust run over the past month, where shares gained over 30%.
First Quarter Performance
The standout driver was the Testing Services segment, which generated $91.4 million in revenue, a 48% increase year-over-year. This growth was fueled by a 17% rise in testing volume to approximately 54,900 tests, combined with a sharp jump in average revenue per test to roughly $1,660. The company noted this included the recognition of prior-period revenue tied to improved collections.
Patient and Digital Solutions also performed well, bringing in $16.0 million, up 33% from the prior year. This was partially offset by a slight 4% decline in Lab Products revenue, which fell to $10.3 million as the company continues to streamline its focus.
Key financial highlights for Q1 2026 include:
- Revenue: $117.7 million (up 39% YoY)
- GAAP Net Income: $2.8 million (compared to a net loss of $10.4 million in Q1 2025)
- Non-GAAP Net Income: $18.1 million (up from $5.4 million)
- Adjusted EBITDA: $18.9 million (up from $4.6 million)
- Free Cash Flow: $0.5 million (compared to a negative $28.2 million in Q1 2025)
Raised Outlook and Strategic Moves
Management boosted its full-year 2026 guidance, now expecting revenue in the range of $447 million to $465 million, up from the previous forecast of $420 million to $444 million. The new midpoint of $456 million sits comfortably above the current analyst sales consensus of $440.6 million. The company also raised its adjusted EBITDA forecast to a range of $43 million to $57 million, up from a prior range of $43 million to $57 million previously.
Beyond the numbers, CareDx made several pivotal strategic announcements during the quarter.
- Divestiture: Announced a definitive agreement to sell its Lab Products business to Eurobio Scientific for $170 million in cash, simplifying its operating model towards higher-margin services.
- Share Buyback: The Board authorized a new $100 million common stock repurchase program over the next 24 months.
- Pipeline: Advanced its lead pipeline program, AlloHeme, through clinical data presentations.
- Partnerships: Expanded integrations with the Epic health record system, with nine transplant centers live and 16 in progress.
Analyst and Earnings Data
For more detailed historical earnings data, future projections, and estimates, please see the links below:
Market Reaction and Outlook
The relatively muted after-market reaction, despite the massive earnings beat and guidance raise, can likely be attributed to profit-taking. The stock had rallied significantly in the weeks leading up to the report, pricing in much of the positive momentum.
With the company now projecting 2026 revenue well above the average analyst estimate and a clear path to sustained profitability, the focus will turn to execution. The next key catalyst will be the company's ability to sustain its testing volume growth and seamlessly integrate its strategic initiatives, including the successful closing of the Lab Products divestiture.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.